Condition: Obsessive-Compulsive Disorder · Psychiatric Disorder · Sponsor: Medical University of Vienna
The main goal of this trial is to demonstrate therapeutic efficacy of low dose ketamine in patients with OCD. We expect that ketamine will alleviate symptoms in the hours following application, but also - if effective - that the anti-OCD effects might last for several days after a single infusion.
This description comes directly from the study's public registry record.
Christoph Kraus, MD PhD · +4314040035680 · christoph.kraus@muv.ac.at
Always discuss trial participation with your own doctor first.
| Medical University of Vienna, Department of Psychiatry and Psychotherapy | Vienna, State of Vienna, Austria | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05577585